Angiogenesis is a key event in the progression of NAFLD (Lefere et al., 2020), and VEGF, supported by the activation of hypoxia‐inducible factors, is a key pro‐angiogenic regulator of this process. The gene discussed is VEGFA; the disease is metabolic dysfunction-associated steatotic liver disease.